|
|
| Type |
Poster Presentation |
| Area |
Medicinal Chemistry |
| Room No. |
Event Hall |
| Time |
4월 19일 (목요일) 11:00~12:30 |
| Code |
MEDI.P-647 |
| Subject |
ScFv-Ferritin as an Advanced Targeted Delivery Platform |
| Authors |
park sunhee, hyo jin kang1, Sang Jeon Chung2,*
Pharmacy, Sungkyunkwan University, Korea
1Department of Chemistry, Dongguk University, Korea
2Department of Chemistry, SungKyunKwan University, Korea
|
| Abstract |
Nanoparticles are increasingly used as labels for analytical purposes and therapy. In general, nanoparticles need to be functionalized with single chain variable fragment (scFv). Protein nanocage can self-assembled spherical structure. Small subunits make cluster and they can assembled and disassembled in unique environment. The particles are based on the globular protein shell of human ferritin light chain (HFL). HFL is a self assemble protein. HFL is composed of 24 subunits, which are self-assembled to form a cage-like nanostructure with external diameter of 8 nm. Single chain variable fragments (scFvs) have potential advantages over whole antibodies, scFvs are one-fifth the size of whole antibodies, they retain full antigen binding capacity. It is smaller than IgG but it can binding with antigen and easily make with E.coli system.
In this study, we developed the therapeutic potential and safety profiles of high affinity protein nanocage (scFv-Ferritin) targeted HER2 antigen which are identified using a scFv variant of Trastuzumab and modified human ferritin light chain. We show that protein nanocage demonstrate high binding affinity and specificity to HER2 antigen. The fluorescence labeled protein nanocage successfully functioned in xenograft models of breast cancer (HER2-overexpressing breast cancer cells). In order to increase the toxicity of nanocage, it was conjugated by maleimide doxorubicin. Doxo conjugated nanocage’s toxicity is measured by MTT assay. It works better than just doxorubicin. Due to its molecular level engineering capability and increased binding avidity, ScFv-ferritin is expected to be a novel delivery platform for theragnosis.
|
| E-mail |
sunny21p@naver.com |
|
121st General Meeting of the KCS